$6.730
-0.079 (-1.17%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
EVMN Prediction & Forecast by Similar Chart Analysis
Alphio's EVMN stock price prediction model matches the current Evommune Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $6.75 (+0.23%). The 1-week path is $6.66 (-1.01%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Evommune Inc Stock?
Evommune, Inc. (EVMN) is not a good buy right now due to its current price of $5.10, which is significantly lower than the analyst price targets, indicating a lack of confidence in the stock's near-term recovery. The RSI is at a low 20.734, suggesting that the stock is oversold, but this does not guarantee a rebound. The company has faced substantial losses, with a net income of -32,246,000 USD in Q2 2026, and a staggering year-to-date change of -70.54%. The main risk is the company's recent drug trial failures, which have led to a negative sentiment shift among investors and a significant drop in share price.
EVMN stock price ended at $6.73 on Friday, after losing -1.17%
Evommune Inc (EVMN) last closed at $6.73, losing -1.17%. These facts feed the 1-day and 1-week EVMN price prediction above.
Forecast Drivers
Evommune Inc (EVMN) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches EVMN, ranked by similarity.
Seasonality analysis for EVMN
Historically the probability of a positive October return for EVMN is 0.00%. March offers the highest probability of a positive month at 100.00%, while July is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.